Short Interest in Capricor Therapeutics, Inc. (NASDAQ:CAPR) Decreases By 69.4%

Capricor Therapeutics, Inc. (NASDAQ:CAPR) was the recipient of a large decline in short interest during the month of December. As of December 15th, there was short interest totaling 5,029,282 shares, a decline of 69.4% from the November 30th total of 16,419,579 shares. Currently, 12.3% of the company’s shares are sold short. Based on an average daily volume of 8,567,200 shares, the days-to-cover ratio is presently 0.6 days. Based on an average daily volume of 8,567,200 shares, the days-to-cover ratio is presently 0.6 days. Currently, 12.3% of the company’s shares are sold short.

Capricor Therapeutics Trading Up 0.0%

Shares of NASDAQ:CAPR traded up $0.01 during trading on Friday, reaching $29.69. The stock had a trading volume of 910,099 shares, compared to its average volume of 5,292,219. The firm’s 50-day simple moving average is $13.78 and its 200 day simple moving average is $9.98. Capricor Therapeutics has a one year low of $4.30 and a one year high of $40.37. The company has a market capitalization of $1.36 billion, a P/E ratio of -16.49 and a beta of 0.61.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($0.54) EPS for the quarter, hitting the consensus estimate of ($0.54). Equities research analysts forecast that Capricor Therapeutics will post -1.21 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on CAPR shares. Maxim Group boosted their target price on Capricor Therapeutics from $25.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, December 4th. Roth Capital upped their price objective on Capricor Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. Oppenheimer lifted their target price on Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th. HC Wainwright lifted their target price on Capricor Therapeutics from $24.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, December 3rd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Capricor Therapeutics in a research report on Monday. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $40.82.

Hedge Funds Weigh In On Capricor Therapeutics

Several hedge funds have recently modified their holdings of CAPR. Farther Finance Advisors LLC acquired a new stake in Capricor Therapeutics in the 3rd quarter worth approximately $28,000. Parkside Financial Bank & Trust purchased a new position in shares of Capricor Therapeutics in the third quarter worth $36,000. Russell Investments Group Ltd. lifted its stake in shares of Capricor Therapeutics by 122.2% during the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock worth $37,000 after buying an additional 2,786 shares during the period. Tower Research Capital LLC TRC lifted its stake in shares of Capricor Therapeutics by 280.8% during the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock worth $67,000 after buying an additional 4,976 shares during the period. Finally, Regal Investment Advisors LLC purchased a new stake in shares of Capricor Therapeutics during the third quarter valued at $92,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.